Stockreport

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc.  (SPRB) 
PDF Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024Topline Data from CAHptain-205 Study of Ti [Read more]